TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/4/24 19:03 | 6/4/24 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | D | P | 15 | 6.35 | 0 | 2 | 0 | 7,089 | I | |||||||||||||||
6/3/24 16:27 | 6/3/24 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | D | P | 15 | 7.37 | 0 | 2 | 0 | 8,088 | I | |||||||||||||||
12/19/22 20:25 | 12/15/22 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | DT | P | 25 | 2.54 | 0 | 10 | 0 | 19,671 | I | |||||||||||||||
9/19/22 16:45 | 9/15/22 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | DT | P | 8 | 4.14 | 0 | 2 | 0 | 20,600 | I | |||||||||||||||
5/25/22 10:22 | 5/23/22 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | DT | P | 48 | 4.83 | 0 | 10 | 0 | 22,121 | I | |||||||||||||||
8/27/21 16:14 | 8/26/21 | HUMA | Humacyte, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Dougan Brady W | NC | DT | P.d | 15,225 | 10.00 | 0 | 1,523 | 7 | 22,411 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |